Pernod Ricard shares are locked into a trading range. This phase will eventually have to end with a return of a clear trend. Investors have an opportunity to buy the stock and target the € 196.
Summary
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
The group shows a rather high level of debt in proportion to its EBITDA.
The firm trades with high earnings multiples: 23.03 times its 2022 earnings per share.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The group usually releases earnings worse than estimated.
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.